PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Novavax COVID-19 vaccine produces immunity

Second dose of treatment generates a response among young people during the Oxford University trial.

Researchers leading the University of Oxford’s Com-COV3 study have delivered results from a study researching the immune response and side-effect profile of ‘mixed’ two-dose COVID-19 vaccine schedules.

The trial unfolded in adolescents aged between 12 and 16 years who received either a full or a one-third dose of the Pfizer-BioNTech COVID-19 vaccine – or a full dose of the Novavax vaccine at least eight weeks after a first full dose of the Pfizer-BioNTech vaccine.

Researchers shared that a mixed schedule using a full dose of Pfizer-BioNTech followed by a full dose of Novavax generated higher antibody and T cell responses and triggered fewer breakthrough infections compared to the licensed full dose Pfizer-BioNTech schedule. Furthermore, the mixed schedule combated both wild-type COVID-19 and Omicron COVID-19 variants.

While all mixed and non-mixed vaccine schedules used in the study demonstrated favourable side effect profiles, participants who received fractional dose Pfizer-BioNTech as their second vaccine also reported fewer and milder side effects compared to the other study groups. Critically, no safety concerns were raised in the 148 participants in the 12 to 16 years age group.

This research becomes the first to report results from a randomised, controlled study analysing the immune response and side-effect profiles of standard and mixed COVID-19 vaccines among adolescents.

Dr Angela Minassian, a chief investigator on the trial at the Oxford Vaccine Group, elaborated: “This study has embodied an incredible effort from our collaborating UK sites and the willing young people who took part. Together we have shown that mixed and fractional doses of COVID-19 vaccine schedules studied are well-tolerated and generate robust immune responses in adolescents for at least eight months.”

She added: “Of particular interest is the enhanced performance of Novavax’s protein subunit vaccine following a dose of Pfizer-BioNTech’s mRNA, compared to the standard two doses of Pfizer-BioNTech mRNA.”

“Amongst participants who had not been infected with COVID-19 before, those in the Novavax group were less likely to report a breakthrough infection than those in the standard Pfizer-BioNTech group. While interpretation should be cautious considering the study’s small sample size, this suggests that a combination of vaccine platforms may result in a greater breadth of protection,” she concluded.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026